RELiZORB is Specifically Designed to Deliver More Absorbable Calories from Enteral Formula
In controlled studies using a well-established porcine model of exocrine pancreatic insufficiency, RELiZORB increased plasma levels of omega-3 fats (DHA and EPA).
Formula hydrolyzed with RELiZORB was associated with a statistically significant increase in total fat absorption and improvement in uptake of omega-3 fatty acids (DHA and EPA) in plasma level over 24-hours compared with non-hydrolyzed formula without Relizorb (p<0.05).*
RELiZORB use increased plasma levels of omega-3 (DHA and EPA) in preclinical studies.
RELiZORB normalized plasma levels of DHA and EPA in a controlled study using a well-established porcine model of exocrine pancreatic insufficiency as seen in the figure below.
RELiZORB use enhanced fat absorption and caloric intake in preclinical studies as demonstrated by improved plasma levels of DHA and EPA over 12 days.*
Higher levels of of fat-soluble vitamins (D and E) were observed with use of RELiZORB after 12 days.*
RELiZORB hydrolyzes available fats in enteral formula.
RELiZORB increases absorbable calories by hydrolyzing greater than 90% of available fats in most enteral formulas tested, including both long-chain triglycerides (LCTs) and medium-chain triglycerides (MCTs).
Proven fat hydrolysis with RELiZORB across a range of enteral formulas.
In most enteral formulas tested, RELiZORB hydrolyzes >90% of available fats into readily absorbable fatty acids and monoglycerides.
Using 500 mL of formula with a pump rate of 120 mL/hr.
Note: Formula manufacturers may change the composition of their formulas, which may affect the operation of RELiZORB. Please refer to formula product websites for recent product descriptions, ingredients, and nutritional information. If you have questions about whether your formula can be used with RELiZORB, please contact RELiZORB Support Services at 1-844-RELiZORB (1-844-735-4967).